BCAX - Bicara Therapeutics

-

$undefined

N/A

(N/A)

Bicara Therapeutics NasdaqGM:BCAX Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Location: 116 Huntington Avenue, Boston, MA, 02116, United States | Website: https://www.bicara.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

53.35M

Cash

462.1M

Avg Qtr Burn

-22.07M

Short % of Float

26.04%

Insider Ownership

11.65%

Institutional Own.

89.24%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.